<DOC>
	<DOCNO>NCT02813226</DOCNO>
	<brief_summary>In study 30 men , advance metastatic Castration-Resistant Prostate Cancer ( CRPC ) plan hormonal treatment , undergo conventional image functional imaging prior treatment post treatment determine change image result prognostic outcome . Patients clinical follow-up every 3 month post randomization one year follow survival Years 2 3 .</brief_summary>
	<brief_title>Assessment New Molecular Imaging Strategies Prostate Cancer</brief_title>
	<detailed_description>In study 30 men , advance metastatic CRPC intend abiraterone acetate enzalutamide hormonal treatment undergo conventional image include 99mTc-Methyl diphosphonate ( MDP ) bone scan Computed Tomography ( CT ) abdomen pelvis , functional image 18F-fluorodeoxyglucose ( FDG ) PET-CT 2- ( 3- ( 1-carboxy-5- [ ( 6- [ 18F ] fluoro-pyridine-3-carbonyl ) -amino ] -pentyl ) -ureido ) -pentanedioic acid ( 18F-DCFPyL ) PET-CT one four week prior hormonal treatment approximately 10 week post hormonal treatment . Prostate Specific Antigen ( PSA ) also obtain baseline every three month first year . Baseline image disease change baseline follow-up imaging 18F-FDG PET-CT 18F-DCFPyL PET-CT compare standard care image ( 99mTc-MDP bone scan CT abdomen/pelvis ) well clinical evaluation include response therapy progression disease . This information could use clinician guide androgen receptor ( AR ) - target therapy . Patients clinical follow-up every 3 month post randomization one year follow survival Years 2 3 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Objectively documented metastatic prostate cancer progression either following : At least one rise PSA minimum one week interval within six week study registration , Radiographic progression soft tissue and/or bone within six week study registration 2 . Ongoing androgen deprivation therapy serum testosterone &lt; 50 ng/dL ( &lt; 1.7 nmol/L ) . 3 . Planned start abiraterone acetate enzalutamide . 1 . Age &lt; 18 year . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 . 3 . Planned receive palliative radiotherapy within next 12 week . 4 . Hemoglobin &lt; 90 g/L independent transfusion . 5 . Platelet count &lt; 50 x 10^9 / L. 6 . Serum albumin &lt; 30 g/L . 7 . Serum creatinine &gt; 1.5 x Upper Limit Normal ( ULN ) calculate creatinine clearance &lt; 30 L/min . 8 . Contraindications FDG . 9 . Inability lie supine imaging PETCT . 10 . Inability undergo CT due know allergy contrast . 11 . Inadequate hepatic function : ( ) Bilirubin &gt; 1.5 x ULN , ( ii ) Serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 3 x ULN 12 . Inability complete study require followup</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>castration-resistant</keyword>
	<keyword>molecular imaging</keyword>
	<keyword>abiraterone acetate</keyword>
	<keyword>enzalutamide</keyword>
	<keyword>metabolic response</keyword>
</DOC>